Pooja Prasad, MD
Advanced Heart Failure and Transplant Cardiology · San Francisco, CANPI 1386175867
Payments from drug & device makers
Across 38 payments — averaging $216.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$3K
- Abbott$2K
- Cvrx, Inc.$2K
- Bayer$1K
- Actelion Pharmaceuticals US, Inc.$469
- United Therapeutics Corporation$175
- plus $144 from 2 others
What the payments were for
- Consulting fees$1,34116%
- Travel & lodging$4,49055%
- Food & beverage$2,19927%
- Education$1982%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 15 | $2,743 |
| Abbott | 7 | $1,832 |
| Cvrx, Inc. | 5 | $1,524 |
| Bayer | 1 | $1,341 |
| Actelion Pharmaceuticals US, Inc. | 6 | $469 |
| United Therapeutics Corporation | 2 | $175 |
| Merck | 1 | $115 |
| Abiomed | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acticor$1,944
- Edora$1,944
- ENSITE PRECISION$1,832
- Rivacor$1,575
- Barostim Neo System$1,524
- Kerendia$1,341
- BioMonitor$1,278
- Solia$1,278
- Sentus$666
- Plexa$666
- WINREVAIR$115
How this compares
$8,228 in reported general payments places this provider in the 30th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 24 | $19,289 |
| Metoprolol Succinate | 13 | $139 |
| Losartan Potassium | 12 | $116 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in San Francisco
- Mandar ArasSan Francisco$1.2M
- Liviu KleinSan Francisco$1.1M
- Marc SimonSan Francisco$651K
- Teresa de MarcoSan Francisco$366K
- Ranjan RaySan Francisco$216K
- Shweta MotiwalaSan Francisco$127K
- Michael PhamSan Francisco$126K
- Michael MartynSan Francisco$93K
- Jared HerrSan Francisco$82K
- van SelbySan Francisco$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.